RU2018100425A - Пегилированный гранулоцитарный колониестимулирующий фактор (гксф) - Google Patents
Пегилированный гранулоцитарный колониестимулирующий фактор (гксф) Download PDFInfo
- Publication number
- RU2018100425A RU2018100425A RU2018100425A RU2018100425A RU2018100425A RU 2018100425 A RU2018100425 A RU 2018100425A RU 2018100425 A RU2018100425 A RU 2018100425A RU 2018100425 A RU2018100425 A RU 2018100425A RU 2018100425 A RU2018100425 A RU 2018100425A
- Authority
- RU
- Russia
- Prior art keywords
- peg
- csf
- hxf
- residue
- histidine residue
- Prior art date
Links
- 238000000034 method Methods 0.000 claims 33
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 20
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 20
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 20
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 12
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 4
- 238000011026 diafiltration Methods 0.000 claims 4
- 239000012528 membrane Substances 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 208000004235 neutropenia Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 201000006681 severe congenital neutropenia Diseases 0.000 claims 1
- 238000011476 stem cell transplantation Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562174373P | 2015-06-11 | 2015-06-11 | |
| US62/174,373 | 2015-06-11 | ||
| US201562184042P | 2015-06-24 | 2015-06-24 | |
| US62/184,042 | 2015-06-24 | ||
| PCT/US2016/037278 WO2016201448A2 (en) | 2015-06-11 | 2016-06-13 | Pegylated granulocyte colony stimulating factor (gcsf) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018100425A true RU2018100425A (ru) | 2019-07-15 |
| RU2018100425A3 RU2018100425A3 (https=) | 2019-11-21 |
Family
ID=57504855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018100425A RU2018100425A (ru) | 2015-06-11 | 2016-06-13 | Пегилированный гранулоцитарный колониестимулирующий фактор (гксф) |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20160361426A1 (https=) |
| EP (1) | EP3307757A4 (https=) |
| JP (1) | JP2018519359A (https=) |
| KR (1) | KR20180017104A (https=) |
| CN (1) | CN107949565A (https=) |
| AU (1) | AU2016277147A1 (https=) |
| CA (1) | CA2988988A1 (https=) |
| IL (1) | IL256167A (https=) |
| MX (1) | MX2017016103A (https=) |
| RU (1) | RU2018100425A (https=) |
| WO (1) | WO2016201448A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023518412A (ja) * | 2020-03-20 | 2023-05-01 | アムジェン インコーポレイテッド | 酸性プロテアーゼを使用するペグフィルグラスチムの遊離ｎ末端の決定 |
| EP4326266A1 (en) * | 2021-04-21 | 2024-02-28 | Celgene Corporation | Methods of treating b-cell lymphoma using combination therapy |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020177688A1 (en) * | 1988-12-22 | 2002-11-28 | Kirin-Amgen, Inc., | Chemically-modified G-CSF |
| US6565841B1 (en) * | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| WO1992016555A1 (en) * | 1991-03-18 | 1992-10-01 | Enzon, Inc. | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
| US5581476A (en) * | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
| US5981709A (en) * | 1997-12-19 | 1999-11-09 | Enzon, Inc. | α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same |
| US6555660B2 (en) * | 2000-01-10 | 2003-04-29 | Maxygen Holdings Ltd. | G-CSF conjugates |
| US6646110B2 (en) * | 2000-01-10 | 2003-11-11 | Maxygen Holdings Ltd. | G-CSF polypeptides and conjugates |
| PL371781A1 (en) * | 2001-07-11 | 2005-06-27 | Maxygen Holdings, Ltd. | G-csf conjugates |
| US7144978B2 (en) * | 2002-01-15 | 2006-12-05 | Pan Asia Bio Co., Ltd. | Multidrop tree branching functional polyethylene glycol, methods of preparing and using same |
| US7410955B2 (en) * | 2002-03-25 | 2008-08-12 | Biosynergen, Inc. | Therapeutic use of agonist ligands specific to G2A receptor |
| US7892745B2 (en) * | 2003-04-24 | 2011-02-22 | Xdx, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| KR101237884B1 (ko) * | 2003-12-03 | 2013-02-27 | 바이오제너릭스 에이지 | 글리코 peg화 과립구 콜로니 자극인자 |
| EP1888119B1 (en) * | 2005-06-01 | 2011-03-09 | Maxygen, Inc. | Pegylated g-csf polypeptides and methods of producing same |
| MX2008001706A (es) * | 2005-08-04 | 2008-04-07 | Nektar Therapeutics Al Corp | Conjugados de una porcion g-csf y un polimero. |
| CU23556A1 (es) * | 2005-11-30 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico |
| WO2009046377A2 (en) * | 2007-10-04 | 2009-04-09 | Medistem Laboratories, Inc. | Compositions and methods of stem cell therapy for autism |
| CN101602801A (zh) * | 2008-06-13 | 2009-12-16 | 杭州九源基因工程有限公司 | 聚乙二醇单修饰的重组人粒细胞集落刺激因子突变体 |
| WO2011041376A1 (en) * | 2009-09-30 | 2011-04-07 | Prolong Pharmaceuticals | Modified granulocyte colony stimulating factor (g-csf) |
| WO2011075606A2 (en) * | 2009-12-18 | 2011-06-23 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
| CN104109235B (zh) * | 2014-05-30 | 2017-07-18 | 厦门赛诺邦格生物科技股份有限公司 | 一种具有氮原子支化中心的单一官能化聚乙二醇、制备方法及其生物相关物质 |
-
2016
- 2016-06-13 JP JP2018516407A patent/JP2018519359A/ja active Pending
- 2016-06-13 EP EP16808533.0A patent/EP3307757A4/en not_active Withdrawn
- 2016-06-13 CA CA2988988A patent/CA2988988A1/en not_active Abandoned
- 2016-06-13 KR KR1020187000596A patent/KR20180017104A/ko not_active Withdrawn
- 2016-06-13 AU AU2016277147A patent/AU2016277147A1/en not_active Abandoned
- 2016-06-13 WO PCT/US2016/037278 patent/WO2016201448A2/en not_active Ceased
- 2016-06-13 US US15/181,333 patent/US20160361426A1/en not_active Abandoned
- 2016-06-13 MX MX2017016103A patent/MX2017016103A/es unknown
- 2016-06-13 RU RU2018100425A patent/RU2018100425A/ru not_active Application Discontinuation
- 2016-06-13 CN CN201680047209.0A patent/CN107949565A/zh active Pending
-
2017
- 2017-12-07 IL IL256167A patent/IL256167A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180017104A (ko) | 2018-02-20 |
| CN107949565A (zh) | 2018-04-20 |
| EP3307757A2 (en) | 2018-04-18 |
| EP3307757A4 (en) | 2019-03-13 |
| WO2016201448A2 (en) | 2016-12-15 |
| RU2018100425A3 (https=) | 2019-11-21 |
| WO2016201448A3 (en) | 2017-02-09 |
| CA2988988A1 (en) | 2016-12-15 |
| AU2016277147A1 (en) | 2018-01-18 |
| MX2017016103A (es) | 2018-05-22 |
| IL256167A (en) | 2018-04-30 |
| US20160361426A1 (en) | 2016-12-15 |
| JP2018519359A (ja) | 2018-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9765114B2 (en) | Method for cancer immunotherapy | |
| AU2015369776A1 (en) | Compositions and methods for generating antigens, antibodies, and immunotherapeutic compositions and methods | |
| CA3072009A1 (en) | Crcx4 inhibitor peptides for the treatment of diseases | |
| CN102458478B (zh) | 白蛋白-淀粉样肽缀合物及其用途 | |
| CA3198757A1 (en) | Aromatic boron-containing compounds and insulin analogs | |
| JP2026035742A (ja) | 生体高分子標的特異的補体阻害剤及びその製造方法と応用 | |
| RU2018100425A (ru) | Пегилированный гранулоцитарный колониестимулирующий фактор (гксф) | |
| CN119285744A (zh) | 逆向-反转肽 | |
| JP2018519359A5 (https=) | ||
| CA2999792A1 (en) | Use of human derived immunosuppressive proteins and peptides as medicaments | |
| US10913780B2 (en) | Conjugates, their compositions, their uses, and their methods of making | |
| CN104945514A (zh) | 一种胰高血糖样素肽-1的融合蛋白、其制备方法及其药物组合物 | |
| US9969773B2 (en) | Polymers, pharmaceutical compositions and methods of synthesizing the same | |
| JP7341451B2 (ja) | タンパク質性化合物とその利用 | |
| WO2024151501A1 (en) | Novel imidazopyrimidine compound and uses thereof | |
| RU2792848C2 (ru) | Полипептиды для лечения заболеваний | |
| KR20240145409A (ko) | 신규한 그랜자임 융합단백질 및 이의 용도 | |
| CN106188233B (zh) | 一种治疗金葡菌奶牛乳房炎的多肽及制备工艺 | |
| KR20250117319A (ko) | 미토콘드리아 기능 개선 펩타이드의 항암 용도 | |
| US10081660B2 (en) | Polynucleotide, polypeptide with immunosuppressive activity, expression cassette, expression vector, host cell, pharmaceutical composition, methods for producing a polypeptide with immunosuppressive activity and for preventing or treating conditions that require immunosuppression, and use of a polypeptide | |
| CN114957466A (zh) | 一种干细胞在制备人工皮肤中的用途 | |
| HK1122819B (en) | Novel peptide compounds from wilms' tumor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20210114 |